Company:  CTD HOLDINGS INC (CTDH)
Form Type:  DEF 14A
Filing Date:  4/16/2018 
CIK:  0000922247 
Address:  6714 NW 16TH STREET, SUITE B 
City, State, Zip:  GAINSVILLE, Florida 32653 
Telephone:  386-418-8060 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.33  
Change: 
0.025 (8.20%)  
Trade Time: 
Jun 22  
Market Cap: 
$24.26M
Trade CTDH now with 

© 2018  
Description of Business
CTD Holdings, Inc. ("we" "our" "us" or "the Company") was organized as a Florida corporation on August 9, 1990, with operations beginning in July 1992. In conjunction with a restructuring in 2000, we changed our name from Cyclodextrin Technologies Development, Inc., or CTDI, to CTD Holdings, Inc.; CTDI was then incorporated as a Florida corporation and became a wholly owned subsidiary of CTD Holdings, Inc. We are a biotechnology company that develops cyclodextrin-based products for the treatment of disease. We filed a Type II Drug Master File with the U.S. Food and Drug Administration ("FDA") in 2014 for our lead drug candidate, Trappsol® Cyclo(TM) (hydroxypropyl beta cyclodextrin) as a treatment for Niemann-Pick Type C disease ("NPC"). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lung, liver, spleen, and other organs. In 2015, we launched an International Clinical Program for Trappsol® Cyclo(TM) as a treatment for NPC.
Register and access this filing in:     
  FORM DEF 14A
    NOTICE OF SPECIAL MEETING OF SHAREHOLDERS
    PROXY STATEMENT
    PROPOSAL NO. 1
    PROPOSAL NO. 2
    PROPOSAL NO. 3
    OTHER MATTERS
    PRINCIPAL SHAREHOLDERS
      BENEFICIAL OWNERS
    SUBMISSION OF SHAREHOLDER PROPOSALS
    Special Meeting Proxy Card - Common Stock